尋常性天疱瘡の世界市場 - 産業動向と予測（2030年）

世界の尋常性天疱瘡の市場規模は、2022年の3億6,259万米ドルから2030年までに6億7,732万米ドルに達し、2023年～2030年の予測期間中にCAGRで8.2％の成長が予測されています。

当レポートでは、世界の尋常性天疱瘡市場について調査分析し、産業動向と予測、セグメント分析、企業プロファイルなどを提供しています。

目次

第1章 イントロダクション

第2章 市場セグメンテーション

第3章 エグゼクティブサマリー

第4章 重要考察

• PESTEL分析
• ポーターのファイブフォース分析
• 特許分析
• 患者の流れ図
• 主な価格戦略
• 将来の治療法
• 主な患者登録戦略

第5章 パイプライン分析

第6章 疫学

第7章 産業考察

第8章 世界の尋常性天疱瘡市場：規制

第9章 市場の概要

• 促進要因
  • 尋常性天疱瘡の新たな治療オプション
  • 影響を受けた患者に対するNGOの支援の拡大
  • 疾患に関する認識
• 抑制要因
  • 厳格な規制ガイドライン
  • 高い治療費
• 機会
  • 個別化医療に対する需要の増大
  • 医療施設の増加
  • 治療管理に向けたデジタルヘルス技術
• 課題
  • 投薬に伴う副作用
  • 償還と補償の政策

第10章 世界の尋常性天疱瘡市場：診断・治療別

• 概要
• 治療
  • 投薬：タイプ別
  • 投薬：投与経路別
  • 投薬：薬剤タイプ別
• 診断
  • 皮膚生検
  • 血液検査
  • 内視鏡検査

第11章 世界の尋常性天疱瘡市場：人口タイプ別

• 概要
• 成人
• 高齢者
• 小児

第12章 世界の尋常性天疱瘡市場：エンドユーザー別

• 概要
• 病院
• 専門クリニック
• 研究機関
• その他

第13章 世界の尋常性天疱瘡市場：流通チャネル別

• 概要
• 病院薬局
• 小売薬局
• オンライン薬局

第14章 世界の尋常性天疱瘡市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • スイス
  • トルコ
  • ロシア
  • ベルギー
  • オランダ
  • その他の欧州
• アジア太平洋
  • 中国
  • インド
  • 韓国
  • マレーシア
  • 日本
  • オーストラリア
  • シンガポール
  • タイ
  • インドネシア
  • フィリピン
  • その他のアジア太平洋
• 南米
  • ブラジル
  • アルゼンチン
  • その他の南米
• 中東・アフリカ
  • サウジアラビア
  • エジプト
  • アラブ首長国連邦
  • 南アフリカ
  • イスラエル
  • その他の中東・アフリカ

第15章 世界の尋常性天疱瘡市場、企業情勢

• 企業シェア分析：世界
• 企業シェア分析：北米
• 企業シェア分析：欧州
• 企業シェア分析：アジア太平洋

第16章 SWOT分析

第17章 企業プロファイル

• ABBVIE INC.
• MERCK & CO., INC.
• SANOFI
• REGENERON PHARMACEUTICALS INC.
• NOVARTIS AG
• AMGEN INC.
• ASTRAZENECA
• BOEHRINGER INGELHEIM INTERNATIONAL GMBH
• CELLTRION HEALTHCARE CO., LTD
• F. HOFFMANN-LA ROCHE LTD.
• FRESENIUS KABI AG
• GSK PLC
• JOHNSON & JOHNSON SERVICES, INC.
• LILLY
• PFIZER INC.
• RAKSHIT DRUGS PVT. LTD
• TEVA PHARMACEUTICAL INDUSTRIES LTD
• ZYDUS GROUP

第18章 アンケート

第19章 関連レポート

LIST OF TABLES

• TABLE 1 GLOBAL PEMPHIGUS VULGARIS MARKET, PATENT ANALYSIS 57
• TABLE 2 GLOBAL PEMPHIGUS VULGARIS MARKET, PIPELINE ANALYSIS 62
• TABLE 3 GLOBAL PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 78
• TABLE 4 GLOBAL TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 79
• TABLE 5 GLOBAL TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 80
• TABLE 6 GLOBAL STEROID- SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 80
• TABLE 7 GLOBAL ANTI- INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 81
• TABLE 8 GLOBAL TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 83
• TABLE 9 GLOBAL TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 83
• TABLE 10 GLOBAL DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 84
• TABLE 11 GLOBAL DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 85
• TABLE 12 GLOBAL PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 89
• TABLE 13 GLOBAL ADULTS IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 90
• TABLE 14 GLOBAL GERIATRIC IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 91
• TABLE 15 GLOBAL PEDIATRIC IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 92
• TABLE 16 GLOBAL PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 96
• TABLE 17 GLOBAL HOSPITALS IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 97
• TABLE 18 GLOBAL SPECIALTY CLINICS IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 98
• TABLE 19 GLOBAL RESEARCH INSTITUTES IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 98
• TABLE 20 GLOBAL OTHERS IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 99
• TABLE 21 GLOBAL PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 103
• TABLE 22 GLOBAL HOSPITALS PHARMACY IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 104
• TABLE 23 GLOBAL RETAIL PHARMACY IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 105
• TABLE 24 GLOBAL ONLINE PHARMACY IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 105
• TABLE 25 GLOBAL PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 111
• TABLE 26 NORTH AMERICA PEMPHIGUS VULGARIS MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 116
• TABLE 27 NORTH AMERICA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 116
• TABLE 28 NORTH AMERICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 116
• TABLE 29 NORTH AMERICA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 117
• TABLE 30 NORTH AMERICA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 117
• TABLE 31 NORTH AMERICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 117
• TABLE 32 NORTH AMERICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 118
• TABLE 33 NORTH AMERICA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 118
• TABLE 34 NORTH AMERICA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 118
• TABLE 35 NORTH AMERICA PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 119
• TABLE 36 NORTH AMERICA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 119
• TABLE 37 U.S. PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 120
• TABLE 38 U.S. TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 120
• TABLE 39 U.S. STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 121
• TABLE 40 U.S. ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 121
• TABLE 41 U.S. TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 121
• TABLE 42 U.S. TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 122
• TABLE 43 U.S. DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 122
• TABLE 44 U.S. PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 122
• TABLE 45 U.S. PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 122
• TABLE 46 U.S. PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 123
• TABLE 47 CANADA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 124
• TABLE 48 CANADA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 124
• TABLE 49 CANADA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 125
• TABLE 50 CANADA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 125
• TABLE 51 CANADA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 125
• TABLE 52 CANADA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 126
• TABLE 53 CANADA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 126
• TABLE 54 CANADA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 126
• TABLE 55 CANADA PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 126
• TABLE 56 CANADA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 127
• TABLE 57 MEXICO PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 128
• TABLE 58 MEXICO TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 128
• TABLE 59 MEXICO STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 129
• TABLE 60 MEXICO ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 129
• TABLE 61 MEXICO TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 129
• TABLE 62 MEXICO TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 130
• TABLE 63 MEXICO DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 130
• TABLE 64 MEXICO PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 130
• TABLE 65 MEXICO PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 130
• TABLE 66 MEXICO PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 131
• TABLE 67 EUROPE PEMPHIGUS VULGARIS MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 136
• TABLE 68 EUROPE PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 136
• TABLE 69 EUROPE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 137
• TABLE 70 EUROPE STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 137
• TABLE 71 EUROPE ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 138
• TABLE 72 EUROPE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 138
• TABLE 73 EUROPE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 138
• TABLE 74 EUROPE DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 139
• TABLE 75 EUROPE PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 139
• TABLE 76 EUROPE PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 139
• TABLE 77 EUROPE PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 140
• TABLE 78 GERMANY PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 141
• TABLE 79 GERMANY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 141
• TABLE 80 GERMANY STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 142
• TABLE 81 GERMANY ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 142
• TABLE 82 GERMANY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 142
• TABLE 83 GERMANY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 143
• TABLE 84 GERMANY DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 143
• TABLE 85 GERMANY PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 143
• TABLE 86 GERMANY PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 144
• TABLE 87 GERMANY PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 144
• TABLE 88 U.K. PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 145
• TABLE 89 U.K. TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 145
• TABLE 90 U.K. STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 146
• TABLE 91 U.K. ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 146
• TABLE 92 U.K. TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 146
• TABLE 93 U.K. TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 147
• TABLE 94 U.K. DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 147
• TABLE 95 U.K. PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 147
• TABLE 96 U.K. PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 147
• TABLE 97 U.K. PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 148
• TABLE 98 FRANCE PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 149
• TABLE 99 FRANCE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 149
• TABLE 100 FRANCE STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 150
• TABLE 101 FRANCE ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 150
• TABLE 102 FRANCE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 150
• TABLE 103 FRANCE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 151
• TABLE 104 FRANCE DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 151
• TABLE 105 FRANCE PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 151
• TABLE 106 FRANCE PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 151
• TABLE 107 FRANCE PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 152
• TABLE 108 ITALY PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 153
• TABLE 109 ITALY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 153
• TABLE 110 ITALY STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 154
• TABLE 111 ITALY ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 154
• TABLE 112 ITALY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 154
• TABLE 113 ITALY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 155
• TABLE 114 ITALY DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 155
• TABLE 115 ITALY PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 155
• TABLE 116 ITALY PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 155
• TABLE 117 ITALY PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 156
• TABLE 118 SPAIN PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 157
• TABLE 119 SPAIN TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 157
• TABLE 120 SPAIN STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 158
• TABLE 121 SPAIN ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 158
• TABLE 122 SPAIN TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 158
• TABLE 123 SPAIN TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 159
• TABLE 124 SPAIN DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 159
• TABLE 125 SPAIN PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 159
• TABLE 126 SPAIN PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 159
• TABLE 127 SPAIN PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 160
• TABLE 128 SWITZERLAND PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 161
• TABLE 129 SWITZERLAND TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 161
• TABLE 130 SWITZERLAND STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 162
• TABLE 131 SWITZERLAND ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 162
• TABLE 132 SWITZERLAND TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 162
• TABLE 133 SWITZERLAND TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 162
• TABLE 134 SWITZERLAND DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 163
• TABLE 135 SWITZERLAND PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 163
• TABLE 136 SWITZERLAND PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 163
• TABLE 137 SWITZERLAND PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 164
• TABLE 138 TURKEY PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 165
• TABLE 139 TURKEY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 165
• TABLE 140 TURKEY STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 166
• TABLE 141 TURKEY ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 166
• TABLE 142 TURKEY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 166
• TABLE 143 TURKEY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 167
• TABLE 144 TURKEY DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 167
• TABLE 145 TURKEY PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 167
• TABLE 146 TURKEY PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 167
• TABLE 147 TURKEY PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 168
• TABLE 148 RUSSIA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 169
• TABLE 149 RUSSIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 169
• TABLE 150 RUSSIA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 170
• TABLE 151 RUSSIA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 170
• TABLE 152 RUSSIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 170
• TABLE 153 RUSSIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 171
• TABLE 154 RUSSIA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 171
• TABLE 155 RUSSIA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 171
• TABLE 156 RUSSIA PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 171
• TABLE 157 RUSSIA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 172
• TABLE 158 BELGIUM PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 173
• TABLE 159 BELGIUM TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 173
• TABLE 160 BELGIUM STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 174
• TABLE 161 BELGIUM ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 174
• TABLE 162 BELGIUM TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 174
• TABLE 163 BELGIUM TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 175
• TABLE 164 BELGIUM DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 175
• TABLE 165 BELGIUM PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 175
• TABLE 166 BELGIUM PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 175
• TABLE 167 BELGIUM PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 176
• TABLE 168 NETHERLANDS PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 177
• TABLE 169 NETHERLANDS TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 177
• TABLE 170 NETHERLANDS STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 178
• TABLE 171 NETHERLANDS ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 178
• TABLE 172 NETHERLANDS TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 178
• TABLE 173 NETHERLANDS TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 178
• TABLE 174 NETHERLANDS DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 179
• TABLE 175 NETHERLANDS PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 179
• TABLE 176 NETHERLANDS PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 179
• TABLE 177 NETHERLANDS PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 179
• TABLE 178 REST OF EUROPE PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 180
• TABLE 179 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 185
• TABLE 180 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 185
• TABLE 181 ASIA-PACIFIC TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 186
• TABLE 182 ASIA-PACIFIC STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 186
• TABLE 183 ASIA-PACIFIC ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 187
• TABLE 184 ASIA-PACIFIC TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 187
• TABLE 185 ASIA-PACIFIC TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 187
• TABLE 186 ASIA-PACIFIC DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 188
• TABLE 187 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 188
• TABLE 188 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 188
• TABLE 189 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 189
• TABLE 190 CHINA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 190
• TABLE 191 CHINA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 190
• TABLE 192 CHINA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 191
• TABLE 193 CHINA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 191
• TABLE 194 CHINA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 191
• TABLE 195 CHINA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 192
• TABLE 196 CHINA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 192
• TABLE 197 CHINA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 192
• TABLE 198 CHINA PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 192
• TABLE 199 CHINA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 193
• TABLE 200 INDIA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 194
• TABLE 201 INDIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 194
• TABLE 202 INDIA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 195
• TABLE 203 INDIA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 195
• TABLE 204 INDIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 195
• TABLE 205 INDIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 196
• TABLE 206 INDIA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 196
• TABLE 207 INDIA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 196

• TABLE 208 INDIA PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 196
• TABLE 209 INDIA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 197
• TABLE 210 SOUTH KOREA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 198
• TABLE 211 SOUTH KOREA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 198
• TABLE 212 SOUTH KOREA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 199
• TABLE 213 SOUTH KOREA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 199
• TABLE 214 SOUTH KOREA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 199
• TABLE 215 SOUTH KOREA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 200
• TABLE 216 SOUTH KOREA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 200
• TABLE 217 SOUTH KOREA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 200
• TABLE 218 SOUTH KOREA PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 201
• TABLE 219 SOUTH KOREA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 201
• TABLE 220 MALAYSIA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 202
• TABLE 221 MALAYSIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 202
• TABLE 222 MALAYSIA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 203
• TABLE 223 MALAYSIA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 203
• TABLE 224 MALAYSIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 203
• TABLE 225 MALAYSIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 204
• TABLE 226 MALAYSIA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 204
• TABLE 227 MALAYSIA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 204
• TABLE 228 MALAYSIA PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 205
• TABLE 229 MALAYSIA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 205
• TABLE 230 JAPAN PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 206
• TABLE 231 JAPAN TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 206
• TABLE 232 JAPAN STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 206
• TABLE 233 JAPAN ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 207
• TABLE 234 JAPAN TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 207
• TABLE 235 JAPAN TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 207
• TABLE 236 JAPAN DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 208
• TABLE 237 JAPAN PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 208
• TABLE 238 JAPAN PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 208
• TABLE 239 JAPAN PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 209
• TABLE 240 AUSTRALIA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 210
• TABLE 241 AUSTRALIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 210
• TABLE 242 AUSTRALIA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 211
• TABLE 243 AUSTRALIA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 211
• TABLE 244 AUSTRALIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 211
• TABLE 245 AUSTRALIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 212
• TABLE 246 AUSTRALIA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 212
• TABLE 247 AUSTRALIA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 212
• TABLE 248 AUSTRALIA PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 213
• TABLE 249 AUSTRALIA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 213
• TABLE 250 SINGAPORE PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 214
• TABLE 251 SINGAPORE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 214
• TABLE 252 SINGAPORE STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 215
• TABLE 253 SINGAPORE ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 215
• TABLE 254 SINGAPORE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 215
• TABLE 255 SINGAPORE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 216
• TABLE 256 SINGAPORE DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 216
• TABLE 257 SINGAPORE PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 216
• TABLE 258 SINGAPORE PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 217
• TABLE 259 SINGAPORE PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 217
• TABLE 260 THAILAND PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 218
• TABLE 261 THAILAND TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 218
• TABLE 262 THAILAND STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 219
• TABLE 263 THAILAND ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 219
• TABLE 264 THAILAND TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 219
• TABLE 265 THAILAND TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 220
• TABLE 266 THAILAND DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 220
• TABLE 267 THAILAND PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 220
• TABLE 268 THAILAND PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 221
• TABLE 269 THAILAND PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 221
• TABLE 270 INDONESIA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 222
• TABLE 271 INDONESIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 222
• TABLE 272 INDONESIA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 222
• TABLE 273 INDONESIA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 223
• TABLE 274 INDONESIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 223
• TABLE 275 INDONESIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 223
• TABLE 276 INDONESIA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 224
• TABLE 277 INDONESIA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 224
• TABLE 278 INDONESIA PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 224
• TABLE 279 INDONESIA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 225
• TABLE 280 PHILIPPINES PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 226
• TABLE 281 PHILIPPINES TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 226
• TABLE 282 PHILIPPINES STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 226
• TABLE 283 PHILIPPINES ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 227
• TABLE 284 PHILIPPINES TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 227
• TABLE 285 PHILIPPINES TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 227
• TABLE 286 PHILIPPINES DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 227
• TABLE 287 PHILIPPINES PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 228
• TABLE 288 PHILIPPINES PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 228
• TABLE 289 PHILIPPINES PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 228
• TABLE 290 REST OF ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 229
• TABLE 291 SOUTH AMERICA PEMPHIGUS VULGARIS MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 234
• TABLE 292 SOUTH AMERICA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 234
• TABLE 293 SOUTH AMERICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 234
• TABLE 294 SOUTH AMERICA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 235
• TABLE 295 SOUTH AMERICA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 235
• TABLE 296 SOUTH AMERICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 235
• TABLE 297 SOUTH AMERICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 236
• TABLE 298 SOUTH AMERICA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 236
• TABLE 299 SOUTH AMERICA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 236
• TABLE 300 SOUTH AMERICA PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 237
• TABLE 301 BRAZIL PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 238
• TABLE 302 BRAZIL TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 238
• TABLE 303 BRAZIL STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 239
• TABLE 304 BRAZIL ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 239
• TABLE 305 BRAZIL TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 239
• TABLE 306 BRAZIL TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 240
• TABLE 307 BRAZIL DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 240
• TABLE 308 BRAZIL PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 240
• TABLE 309 BRAZIL PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 240
• TABLE 310 BRAZIL PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 241
• TABLE 311 ARGENTINA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 242
• TABLE 312 ARGENTINA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 242
• TABLE 313 ARGENTINA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 243
• TABLE 314 ARGENTINA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 243
• TABLE 315 ARGENTINA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 243
• TABLE 316 ARGENTINA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 244
• TABLE 317 ARGENTINA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 244
• TABLE 318 ARGENTINA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 244
• TABLE 319 ARGENTINA PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 245
• TABLE 320 ARGENTINA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 245
• TABLE 321 REST OF SOUTH AMERICA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 246
• TABLE 322 MIDDLE EAST AND AFRICA PEMPHIGUS VULGARIS MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 251
• TABLE 323 MIDDLE EAST AND AFRICA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 251
• TABLE 324 MIDDLE EAST AND AFRICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 251
• TABLE 325 MIDDLE EAST AND AFRICA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 252
• TABLE 326 MIDDLE EAST AND AFRICA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 252
• TABLE 327 MIDDLE EAST AND AFRICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 252
• TABLE 328 MIDDLE EAST AND AFRICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 253
• TABLE 329 MIDDLE EAST AND AFRICA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 253
• TABLE 330 MIDDLE EAST AND AFRICA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 253
• TABLE 331 MIDDLE EAST AND AFRICA PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 254
• TABLE 332 MIDDLE EAST AND AFRICA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 254
• TABLE 333 SAUDI ARABIA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 255
• TABLE 334 SAUDI ARABIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 255
• TABLE 335 SAUDI ARABIA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 256
• TABLE 336 SAUDI ARABIA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 256
• TABLE 337 SAUDI ARABIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 256
• TABLE 338 SAUDI ARABIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 257
• TABLE 339 SAUDI ARABIA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 257
• TABLE 340 SAUDI ARABIA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 257
• TABLE 341 SAUDI ARABIA PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 258
• TABLE 342 SAUDI ARABIA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 258
• TABLE 343 EGYPT PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 259
• TABLE 344 EGYPT TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 259
• TABLE 345 EGYPT STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 260
• TABLE 346 EGYPT ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 260
• TABLE 347 EGYPT TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 260
• TABLE 348 EGYPT TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 261
• TABLE 349 EGYPT DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 261
• TABLE 350 EGYPT PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 261
• TABLE 351 EGYPT PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 261
• TABLE 352 EGYPT PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 262
• TABLE 353 U.A.E. PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 263
• TABLE 354 U.A.E. TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 263
• TABLE 355 U.A.E. STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 264
• TABLE 356 U.A.E. ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 264
• TABLE 357 U.A.E. TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 264
• TABLE 358 U.A.E. TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 265
• TABLE 359 U.A.E. DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 265
• TABLE 360 U.A.E. PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 265
• TABLE 361 U.A.E. PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 265
• TABLE 362 U.A.E. PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 266
• TABLE 363 SOUTH AFRICA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 267
• TABLE 364 SOUTH AFRICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 267
• TABLE 365 SOUTH AFRICA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 268
• TABLE 366 SOUTH AFRICA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 268
• TABLE 367 SOUTH AFRICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 268
• TABLE 368 SOUTH AFRICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 269
• TABLE 369 SOUTH AFRICA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 269
• TABLE 370 SOUTH AFRICA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 269
• TABLE 371 SOUTH AFRICA PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 270
• TABLE 372 SOUTH AFRICA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 270

LIST OF FIGURES

• FIGURE 1 GLOBAL PEMPHIGUS VULGARIS MARKET: SEGMENTATION 37
• FIGURE 2 GLOBAL PEMPHIGUS VULGARIS MARKET: DATA TRIANGULATION 40
• FIGURE 3 GLOBAL PEMPHIGUS VULGARIS MARKET: DROC ANALYSIS 41
• FIGURE 4 GLOBAL PEMPHIGUS VULGARIS MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS 42
• FIGURE 5 GLOBAL PEMPHIGUS VULGARIS MARKET: COMPANY RESEARCH ANALYSIS 42
• FIGURE 6 GLOBAL PEMPHIGUS VULGARIS MARKET: INTERVIEW DEMOGRAPHICS 43
• FIGURE 7 GLOBAL PEMPHIGUS VULGARIS MARKET: MARKET APPLICATION COVERAGE GRID 45
• FIGURE 8 GLOBAL PEMPHIGUS VULGARIS MARKET: DBMR MARKET POSITION GRID 47
• FIGURE 9 GLOBAL PEMPHIGUS VULGARIS MARKET: VENDOR SHARE ANALYSIS 48
• FIGURE 10 GLOBAL PEMPHIGUS VULGARIS MARKET: SEGMENTATION 51
• FIGURE 11 THE EMERGING TREATMENT OPTIONS FOR THE PEMPHIGUS VULGARISIS EXPECTED TO DRIVE THE GROWTH OF THE GLOBAL PEMPHIGUS VULGARIS MARKET FROM 2023 TO 2030 52
• FIGURE 12 THE DIAGNOSIS AND TREATMENT SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL PEMPHIGUS VULGARIS MARKET IN 2023 AND 2030 52
• FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL PEMPHIGUS VULGARIS MARKET, AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2023 TO 2030 53
• FIGURE 14 ASIA-PACIFIC IS THE FASTEST-GROWING MARKET FOR PEMPHIGUS VULGARIS MARKET MANUFACTURERS IN THE FORECAST PERIOD OF 2023 TO 2030 54
• FIGURE 15 PATIENT FLOW DESCRIPTION OF PEMPHIGUS VULGARIS:- 58
• FIGURE 16 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF GLOBAL PEMPHIGUS VULGARIS MARKET 69
• FIGURE 17 GLOBAL PEMPHIGUS VULGARIS MARKET: BY DIAGNOSIS AND TREATMENT, 2022 76
• FIGURE 18 GLOBAL PEMPHIGUS VULGARIS MARKET: BY DIAGNOSIS AND TREATMENT, 2023-2030 (USD MILLION) 77
• FIGURE 19 GLOBAL PEMPHIGUS VULGARIS MARKET: BY DIAGNOSIS AND TREATMENT, CAGR (2023-2030) 77
• FIGURE 20 GLOBAL PEMPHIGUS VULGARIS MARKET: BY DIAGNOSIS AND TREATMENT, LIFELINE CURVE 78
• FIGURE 21 GLOBAL PEMPHIGUS VULGARIS MARKET: BY POPULATION TYPE, 2022 87
• FIGURE 22 GLOBAL PEMPHIGUS VULGARIS MARKET: BY POPULATION TYPE, 2023-2030 (USD MILLION) 88
• FIGURE 23 GLOBAL PEMPHIGUS VULGARIS MARKET: BY POPULATION TYPE, CAGR (2023-2030) 88
• FIGURE 24 GLOBAL PEMPHIGUS VULGARIS MARKET: BY POPULATION TYPE, LIFELINE CURVE 89
• FIGURE 25 GLOBAL PEMPHIGUS VULGARIS MARKET: BY END USER, 2022 94
• FIGURE 26 GLOBAL PEMPHIGUS VULGARIS MARKET: BY END USER, 2023-2030 (USD MILLION) 95
• FIGURE 27 GLOBAL PEMPHIGUS VULGARIS MARKET: BY END USER, CAGR (2023-2030) 95
• FIGURE 28 GLOBAL PEMPHIGUS VULGARIS MARKET: BY END USER, LIFELINE CURVE 96
• FIGURE 29 GLOBAL PEMPHIGUS VULGARIS MARKET: BY DISTRIBUTION CHANNEL, 2022 101
• FIGURE 30 GLOBAL PEMPHIGUS VULGARIS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 102
• FIGURE 31 GLOBAL PEMPHIGUS VULGARIS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 102
• FIGURE 32 GLOBAL PEMPHIGUS VULGARIS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 103
• FIGURE 33 GLOBAL PEMPHIGUS VULGARIS MARKET: SNAPSHOT (2022) 108
• FIGURE 34 GLOBAL PEMPHIGUS VULGARIS MARKET: BY REGION (2022) 109
• FIGURE 35 GLOBAL PEMPHIGUS VULGARIS MARKET: BY REGION (2023 & 2030) 109
• FIGURE 36 GLOBAL PEMPHIGUS VULGARIS MARKET: BY REGION (2022 & 2030) 110
• FIGURE 37 GLOBAL PEMPHIGUS VULGARIS MARKET: BY DIAGNOSIS AND TREATMENT (2023 & 2030) 110
• FIGURE 38 NORTH AMERICA PEMPHIGUS VULGARIS MARKET: SNAPSHOT (2022) 113
• FIGURE 39 NORTH AMERICA PEMPHIGUS VULGARIS MARKET: BY COUNTRY (2022) 114
• FIGURE 40 NORTH AMERICA PEMPHIGUS VULGARIS MARKET: BY COUNTRY (2023 & 2030) 114
• FIGURE 41 NORTH AMERICA PEMPHIGUS VULGARIS MARKET: BY COUNTRY (2022 & 2030) 115
• FIGURE 42 NORTH AMERICA PEMPHIGUS VULGARIS MARKET: BY DIAGNOSIS AND TREATMENT (2023-2030) 115
• FIGURE 43 EUROPE PEMPHIGUS VULGARIS MARKET: SNAPSHOT (2022) 133
• FIGURE 44 EUROPE PEMPHIGUS VULGARIS MARKET: BY COUNTRY (2022) 134
• FIGURE 45 EUROPE PEMPHIGUS VULGARIS MARKET: BY COUNTRY (2023 & 2030) 134
• FIGURE 46 EUROPE PEMPHIGUS VULGARIS MARKET: BY COUNTRY (2022 & 2030) 135
• FIGURE 47 EUROPE PEMPHIGUS VULGARIS MARKET: DIAGNOSIS AND TREATMENT (2023-2030) 135
• FIGURE 48 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET: SNAPSHOT (2022) 182
• FIGURE 49 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET: BY COUNTRY (2022) 183
• FIGURE 50 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET: BY COUNTRY (2023 & 2030) 183
• FIGURE 51 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET: BY COUNTRY (2022 & 2030) 184
• FIGURE 52 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET: DIAGNOSIS AND TREATMENT (2023-2030) 184
• FIGURE 53 SOUTH AMERICA PEMPHIGUS VULGARIS MARKET: SNAPSHOT (2022) 231
• FIGURE 54 SOUTH AMERICA PEMPHIGUS VULGARIS MARKET: BY COUNTRY (2022) 232
• FIGURE 55 SOUTH AMERICA PEMPHIGUS VULGARIS MARKET: BY COUNTRY (2023 & 2030) 232
• FIGURE 56 SOUTH AMERICA PEMPHIGUS VULGARIS MARKET: BY COUNTRY (2022 & 2030) 233
• FIGURE 57 SOUTH AMERICA PEMPHIGUS VULGARIS MARKET: DIAGNOSIS AND TREATMENT (2023-2030) 233
• FIGURE 58 MIDDLE EAST AND AFRICA PEMPHIGUS VULGARIS MARKET: SNAPSHOT (2022) 248
• FIGURE 59 MIDDLE EAST AND AFRICA PEMPHIGUS VULGARIS MARKET: BY COUNTRY (2022) 249
• FIGURE 60 MIDDLE EAST AND AFRICA PEMPHIGUS VULGARIS MARKET: BY COUNTRY (2023 & 2030) 249
• FIGURE 61 MIDDLE EAST AND AFRICA PEMPHIGUS VULGARIS MARKET: BY COUNTRY (2022 & 2030) 250
• FIGURE 62 MIDDLE EAST AND AFRICA PEMPHIGUS VULGARIS MARKET: DIAGNOSIS AND TREATMENT (2023-2030) 250
• FIGURE 63 GLOBAL PEMPHIGUS VULGARIS MARKET: COMPANY SHARE 2022 (%) 275
• FIGURE 64 NORTH AMERICA PEMPHIGUS VULGARIS MARKET: COMPANY SHARE 2022 (%) 276
• FIGURE 65 EUROPE PEMPHIGUS VULGARIS MARKET: COMPANY SHARE 2022 (%) 277
• FIGURE 66 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET: COMPANY SHARE 2022 (%) 278

The global Pemphigus Vulgaris market is expected to reach USD 677.32 million by 2030 from USD 362.59 million in 2022, growing at a CAGR of 8.2% during the forecast period of 2023 to 2030.

Market Segmentation:

Global Pemphigus Vulgaris Market, By Diagnosis and Treatment (Diagnosis, Treatment), Population Type (Pediatric, Adults, and Geriatric), End User (Hospitals, Specialty Clinics, Research Institutes, and Others), Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, and Online Pharmacy) - Industry Trends and Forecast to 2030.

Overview of Global Pemphigus Vulgaris Market Dynamics :

• Driver
• Rise in patients with rare diseases such as pemphigus vulgaris
• Restraint
• High cost of treatment
• Opportunity
• Rising healthcare facilities in the developing and underdeveloped countries

Market Players

The key market players operating in the market are:

• F-Hoffmann La Roche Ltd.
• Sanofi
• Regeneron Pharmaceuticals Inc.
• Fresenius Kabi AG
• Boehringer Ingelheim International GmbH
• Johnson & Johnson Services, Inc.
• RAKSHIT DRUGS PVT. LTD
• F. Hoffmann-La Roche Ltd
• Pfizer Inc.
• Celltrion Healthcare Co., Ltd.
• AbbVie Inc.
• Novartis AG
• Amgen Inc.
• Merck & Co., Inc.
• AstraZeneca
• Teva Pharmaceutical Industries Ltd
• Lilly
• Zydus Group
• GSK plc.

TABLE OF CONTENTS

1 INTRODUCTION 32

• 1.1 OBJECTIVES OF THE STUDY 32
• 1.2 MARKET DEFINITION 32
• 1.3 OVERVIEW 32
• 1.4 CURRENCY AND PRICING 34
• 1.5 LIMITATIONS 34
• 1.6 MARKETS COVERED 34

2 MARKET SEGMENTATION 37

• 2.1 MARKETS COVERED 37
• 2.2 GEOGRAPHICAL SCOPE 38
• 2.3 YEARS CONSIDERED FOR THE STUDY 39
• 2.4 DBMR TRIPOD DATA VALIDATION MODEL 40
• 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 43
• 2.6 MULTIVARIATE MODELLING 44
• 2.7 MARKET APPLICATION COVERAGE GRID 45
• 2.8 PRODUCT LIFELINE CURVE 46
• 2.9 DBMR MARKET POSITION GRID 47
• 2.10 VENDOR SHARE ANALYSIS 48
• 2.11 SECONDARY SOURCES 49
• 2.12 ASSUMPTIONS 49

3 EXECUTIVE SUMMARY 50

4 PREMIUM INSIGHTS 52

• 4.1 PESTEL ANALYSIS 55
• 4.2 PORTER FIVE FORCES 56
• 4.3 PATENT ANALYSIS 57
• 4.4 PATIENT FLOW DIAGRAM 58
• 4.5 KEY PRICING STRATEGIES 59
• 4.6 FUTURE THERAPIES 60
• 4.7 KEY PATIENT ENROLLMENT STRATEGIES 61

5 PIPELINE ANALYSIS 62

6 EPIDEMIOLOGY 63

7 INDUSTRY INSIGHTS 64

8 GLOBAL PEMPHIGUS VULGARIS MARKET: REGULATIONS 65

9 MARKET OVERVIEW 68

• 9.1 DRIVERS 70
  • 9.1.1 EMERGING TREATMENT OPTIONS FOR PEMPHIGUS VULGARIS 70
  • 9.1.2 GROWING SUPPORT OF NGOS FOR THE AFFECTED PATIENTS 70
  • 9.1.3 AWARENESS REGARDING THE DISEASE 71
• 9.2 RESTRAINTS 71
  • 9.2.1 STRICT REGULATORY GUIDELINES 71
  • 9.2.2 HIGH TREATMENT COSTS 71
• 9.3 OPPORTUNITIES 72
  • 9.3.1 INCREASING DEMAND FOR PERSONALIZED MEDICINE 72
  • 9.3.2 INCREASING HEALTHCARE FACILITIES 72
  • 9.3.3 DIGITAL HEALTH TECHNOLOGIES FOR TREATMENT MANAGEMENT 73
• 9.4 CHALLENGES 73
  • 9.4.1 ADVERSE EFFECTS ASSOCIATED WITH MEDICATIONS 73
  • 9.4.2 REIMBURSEMENT AND COVERAGE POLICIES 74

10 GLOBAL PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT 75

• 10.1 OVERVIEW 76
• 10.2 TREATMENT 79
  • 10.2.1 MEDICATIONS, BY TYPE 79
    • 10.2.1.1 CORTICOSTEROIDS 80
    • 10.2.1.2 STEROID- SPARING IMMUNOSUPPRESSANT DRUGS 80
      • 10.2.1.2.1 AZATHIOPRINE 81
      • 10.2.1.2.2 MYCOPHENALATE MOFETIL 81
      • 10.2.1.2.3 METHOTREXATE 81
      • 10.2.1.2.4 CYCLOPHOSPHAMIDE 81
      • 10.2.1.2.5 MIZORIBINE 81
      • 10.2.1.2.6 OTHERS 81
    • 10.2.1.3 ANTI- INFLAMMATORY AGENTS 81
      • 10.2.1.3.1 DIAMINODYPHENYL SULFONE 82
      • 10.2.1.3.2 TETRACYCLINE 82
      • 10.2.1.3.3 OTHERS 82
    • 10.2.1.4 BIOLOGICS 82
    • 10.2.1.5 INTRAVENOUS IMMUNOGLOBULIN 82
    • 10.2.1.6 ANTIBIOTICS 82
    • 10.2.1.7 ANTIFUNGALS 82
    • 10.2.1.8 ANTIVIRALS 82
    • 10.2.1.9 OTHER MEDICATIONS 82
  • 10.2.2 MEDICATIONS, BY ROUTE OF ADMINISTRATION 82
    • 10.2.2.1 ORAL 83
    • 10.2.2.2 TOPICAL 83
    • 10.2.2.3 PARENTERAL 83
    • 10.2.2.4 OTHERS 83
  • 10.2.3 MEDICATIONS, BY DRUG TYPE 83
    • 10.2.3.1 GENERIC 84
    • 10.2.3.2 BRANDED 84
• 10.3 DIAGNOSIS 84
  • 10.3.1 SKIN BIOPSY 85
  • 10.3.2 BLOOD TEST 85
  • 10.3.3 ENDOSCOPY 85

11 GLOBAL PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE 86

• 11.1 OVERVIEW 87
• 11.2 ADULTS 90
• 11.3 GERIATRIC 91
• 11.4 PEDIATRIC 92

12 GLOBAL PEMPHIGUS VULGARIS MARKET, BY END USER 93

• 12.1 OVERVIEW 94
• 12.2 HOSPITALS 97
• 12.3 SPECIALTY CLINICS 97
• 12.4 RESEARCH INSTITUTES 98
• 12.5 OTHERS 99

13 GLOBAL PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL 100

• 13.1 OVERVIEW 101
• 13.2 HOSPITALS PHARMACY 104
• 13.3 RETAIL PHARMACY 104
• 13.4 ONLINE PHARMACY 105

14 GLOBAL PEMPHIGUS VULGARIS MARKET, BY REGION 106

• 14.1 OVERVIEW 107
• 14.2 NORTH AMERICA 112
  • 14.2.1 U.S. 120
  • 14.2.2 CANADA 124
  • 14.2.3 MEXICO 128
• 14.3 EUROPE 132
  • 14.3.1 GERMANY 141
  • 14.3.2 U.K. 145
  • 14.3.3 FRANCE 149
  • 14.3.4 ITALY 153
  • 14.3.5 SPAIN 157
  • 14.3.6 SWITZERLAND 161
  • 14.3.7 TURKEY 165
  • 14.3.8 RUSSIA 169
  • 14.3.9 BELGIUM 173
  • 14.3.10 NETHERLANDS 177
  • 14.3.11 REST OF EUROPE 180
• 14.4 ASIA-PACIFIC 181
  • 14.4.1 CHINA 190
  • 14.4.2 INDIA 194
  • 14.4.3 SOUTH KOREA 198
  • 14.4.4 MALAYSIA 202
  • 14.4.5 JAPAN 206
  • 14.4.6 AUSTRALIA 210
  • 14.4.7 SINGAPORE 214
  • 14.4.8 THAILAND 218
  • 14.4.9 INDONESIA 222
  • 14.4.10 PHILIPPINES 226
  • 14.4.11 REST OF ASIA-PACIFIC 229
• 14.5 SOUTH AMERICA 230
  • 14.5.1 BRAZIL 238
  • 14.5.2 ARGENTINA 242
  • 14.5.3 REST OF SOUTH AMERICA 246
• 14.6 MIDDLE EAST AND AFRICA 247
  • 14.6.1 SAUDI ARABIA 255
  • 14.6.2 EGYPT 259
  • 14.6.3 U.A.E. 263
  • 14.6.4 SOUTH AFRICA 267
  • 14.6.5 ISRAEL 271
  • 14.6.6 REST OF MIDDLE EAST AND AFRICA 274

15 GLOBAL PEMPHIGUS VULGARIS MARKET, COMPANY LANDSCAPE 275

• 15.1 COMPANY SHARE ANALYSIS: GLOBAL 275
• 15.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 276
• 15.3 COMPANY SHARE ANALYSIS: EUROPE 277
• 15.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 278

16 SWOT ANALYSIS 279

17 COMPANY PROFILE 280

• 17.1 ABBVIE INC. 280
  • 17.1.1 COMPANY SNAPSHOT 280
  • 17.1.2 REVENUE ANALYSIS 280
  • 17.1.3 COMPANY SHARE ANALYSIS 281
  • 17.1.4 PRODUCT PORTFOLIO 281
  • 17.1.5 RECENT DEVELOPMENTS 282
• 17.2 MERCK & CO., INC., 283
  • 17.2.1 COMPANY SNAPSHOT 283
  • 17.2.2 REVENUE ANALYSIS 283
  • 17.2.3 COMPANY SHARE ANALYSIS 284
  • 17.2.4 PRODUCT PORTFOLIO 284
  • 17.2.5 RECENT DEVELOPMENT 284
• 17.3 SANOFI 285
  • 17.3.1 COMPANY SNAPSHOT 285
  • 17.3.2 REVENUE ANALYSIS 285
  • 17.3.3 COMPANY SHARE ANALYSIS 286
  • 17.3.4 PRODUCT PORTFOLIO 286
  • 17.3.5 RECENT DEVELOPMENT 286
• 17.4 REGENERON PHARMACEUTICALS INC. 287
  • 17.4.1 COMPANY SNAPSHOT 287
  • 17.4.2 REVENUE ANALYSIS 287
  • 17.4.3 COMPANY SHARE ANALYSIS 288
  • 17.4.4 PRODUCT PORTFOLIO 288
  • 17.4.5 RECENT DEVELOPMENT 288
• 17.5 NOVARTIS AG 289
  • 17.5.1 COMPANY SNAPSHOT 289
  • 17.5.2 REVENUE ANALYSIS 289
  • 17.5.3 COMPANY SHARE ANALYSIS 290
  • 17.5.4 PRODUCT PORTFOLIO 290
  • 17.5.5 RECENT DEVELOPMENT 290
• 17.6 AMGEN INC. 291
  • 17.6.1 COMPANY SNAPSHOT 291
  • 17.6.2 REVENUE ANALYSIS 291
  • 17.6.3 PRODUCT PORTFOLIO 292
  • 17.6.4 RECENT DEVELOPMENTS 292
• 17.7 ASTRAZENECA 293
  • 17.7.1 COMPANY SNAPSHOT 293
  • 17.7.2 REVENUE ANALYSIS 293
  • 17.7.3 COMPANY SHARE ANALYSIS 294
  • 17.7.4 PRODUCT PORTFOLIO 294
  • 17.7.5 RECENT DEVELOPMENTS 295
• 17.8 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 296
  • 17.8.1 COMPANY SNAPSHOT 296
  • 17.8.2 REVENUE ANALYSIS 296
  • 17.8.3 PRODUCT PORTFOLIO 297
  • 17.8.4 RECENT DEVELOPMENT 297
• 17.9 CELLTRION HEALTHCARE CO., LTD 298
  • 17.9.1 COMPANY SNAPSHOT 298
  • 17.9.2 REVENUE ANALYSIS 298
  • 17.9.3 PRODUCT PORTFOLIO 299
  • 17.9.4 RECENT DEVELOPMENTS 299
• 17.10 F. HOFFMANN- LA ROCHE LTD. 300
  • 17.10.1 COMPANY SNAPSHOT 300
  • 17.10.2 REVENUE ANALYSIS 300
  • 17.10.3 PRODUCT PORTFOLIO 301
  • 17.10.4 RECENT DEVELOPMENT 301
• 17.11 FRESENIUS KABI AG 302
  • 17.11.1 COMPANY SNAPSHOT 302
  • 17.11.2 REVENUE ANALYSIS 302
  • 17.11.3 PRODUCT PORTFOLIO 303
  • 17.11.4 RECENT DEVELOPMENT 303
• 17.12 GSK PLC 304
  • 17.12.1 COMPANY SNAPSHOT 304
  • 17.12.2 REVENUE ANALYSIS 304
  • 17.12.3 PRODUCT PORTFOLIO 305
  • 17.12.4 RECENT DEVELOPMENT 305
• 17.13 JOHNSON & JOHNSON SERVICES, INC. 306
  • 17.13.1 COMPANY SNAPSHOT 306
  • 17.13.2 REVENUE ANALYSIS 306
  • 17.13.3 COMPANY SHARE ANALYSIS 307
  • 17.13.4 PRODUCT PORTFOLIO 307
  • 17.13.5 RECENT DEVELOPMENT 307
• 17.14 LILLY 308
  • 17.14.1 COMPANY SNAPSHOT 308
  • 17.14.2 REVENUE ANALYSIS 308
  • 17.14.3 PRODUCT PORTFOLIO 309
  • 17.14.4 RECENT DEVELOPMENT 309
• 17.15 PFIZER INC. 310
  • 17.15.1 COMPANY SNAPSHOT 310
  • 17.15.2 REVENUE ANALYSIS 310
  • 17.15.3 PRODUCT PORTFOLIO 311
  • 17.15.4 RECENT DEVELOPMENT 311
• 17.16 RAKSHIT DRUGS PVT. LTD 312
  • 17.16.1 COMPANY SNAPSHOT 312
  • 17.16.2 PRODUCT PORTFOLIO 312
  • 17.16.3 RECENT DEVELOPMENT 312
• 17.17 TEVA PHARMACEUTICAL INDUSTRIES LTD 313
  • 17.17.1 COMPANY SNAPSHOT 313
  • 17.17.2 REVENUE ANALYSIS 313
  • 17.17.3 PRODUCT PORTFOLIO 314
  • 17.17.4 RECENT DEVELOPMENT 314
• 17.18 ZYDUS GROUP 315
  • 17.18.1 COMPANY SNAPSHOT 315
  • 17.18.2 REVENUE ANALYSIS 315
  • 17.18.3 PRODUCT PORTFOLIO 316
  • 17.18.4 RECENT DEVELOPMENT 316

18 QUESTIONNAIRE 317

19 RELATED REPORTS 319